CD8A and neoplasm: Molecular analyses performed on tumor samples from patients enrolled in the IMBRAVE150 study highlight the importance of pre-existing immunity—defined as a high expression of CD274 (PD-L1), T-effector signature (CXCL9, PRF1, GZMB), and intratumoral CD8+ T cell density—in terms of clinical response to ICI [20].